A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (NCT05589896)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
- Ossium HPC Marrow, Bone Marrow Transplant (OTHER)
- Pre-transplant conditioning - Myeloablative (MAC) (OTHER)
- Pre-transplant conditioning - Reduced Intensity (RIC) (OTHER)
- Post-transplant treatment (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- City of Hope — Duarte, California
- Moffitt Cancer Center — Tampa, Florida
- Emory University - Winship Cancer Institute — Atlanta, Georgia
- Henry Ford Cancer Institute — Detroit, Michigan
- Oregon Health and Science University — Portland, Oregon
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- St. David's South Austin Medical Center — Austin, Texas
- Methodist Hospital, Texas Transplant — San Antonio, Texas
- University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Leukemia
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma — La Jolla, California
- ATG Plus PTCy vs ATG for CGVHD Prophylaxis — Darlinghurst, New South Wales
- Cancer Stem Cells in Acute Leukemia — Fargo, North Dakota
- A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors — Duarte, California
- Prevention of Hospital Acquired Deconditioning in Hospitalized Acute Leukemia Patients — Manhasset, New York
Explore by condition: All Acute Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.